Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Dolomite Bio scientist demonstrating pipetting into the Nadia Go
Expanding precision medicine, ARTIS icono is designed to enable a wide procedure mix in a single interventional suite
The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV patients.
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
SK Capital’s investment will serve as a catalyst for a new strategic direction as the Company seeks to deepen and expand its presence in fine chemistries for the global life science market.
The Allurion Program is suited for people who are unable to achieve their weight-loss goals by dieting alone or for those who do not want to, or cannot, undergo invasive surgery or endoscopy
Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
